Stage 4 lung adenocarcinoma: brain surgery followed by immunotherapy response

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: PD-L1-positive; EGFR wild-type/no mutation; ALK rearrangement not detected; TTF-1-positive; Napsin A-positive

Metastatic Site: brain

As of March 2024, after 31 cycles of zimberelimab, the lung lesion had shown partial response, brain metastasis had not recurred, and the patient had 24-month progression-free and intracranial recurrence-free survival with normal quality of life.

PubMed CentralRead more →

Stage II lung adenocarcinoma with a fetal-type component treated with surgery

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: PD-L1 negative; no alterations identified on Oncomine Dx testing

He was doing well without recurrence 8 months after surgery.

PubMed CentralRead more →

Stage II Lung Cancer: Ed's Survivor Story

Patient Info: Ed Ackerman, Male, 60s | Stage II

Follow-up tests and scans showed Ed was cancer-free after lung resection and 4 rounds of chemotherapy for Stage IIA lung cancer.

Cleveland ClinicRead more →

Stage III squamous lung cancer complicated by a fatal postoperative bronchopleural fistula

Patient Info: Anonymized, male, 40s | Stage III

He developed a postoperative bronchopleural fistula with pulmonary infection and worsening respiratory failure, and died on December 2, 2020.

PubMed CentralRead more →

Stage III squamous lung cancer with a postoperative bronchopleural fistula successfully repaired

Patient Info: Anonymized, male, 50s | Stage III

After bronchoscopic repair of a postoperative bronchopleural fistula, he was followed for more than 1 year with CT every 3 months and no lung-cancer recurrence.

PubMed CentralRead more →

Stage III squamous lung cancer with a postoperative bronchopleural fistula that resolved with treatment

Patient Info: Anonymized, male, 60s | Stage III

The postoperative bronchopleural fistula resolved after anti-infective treatment, and serial CT scans showed no lung-cancer recurrence during ongoing follow-up.

PubMed CentralRead more →

Stage III lung adenocarcinoma with a postoperative bronchopleural fistula and no recurrence

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: EGFR, ALK, KRAS, RET and ROS1 negative

After treatment of a postoperative bronchopleural fistula, she was followed for more than 1 year with CT every 3 months and no lung-cancer recurrence.

PubMed CentralRead more →

Stage I lung adenocarcinoma diagnosed alongside follicular lymphoma

Patient Info: Anonymized, male, 60s | Stage I

A 69-year-old man was found to have Stage I lung adenocarcinoma and a separate follicular lymphoma, allowing each cancer to be managed independently.

PubMed CentralRead more →

Rare non-small cell lung cancer with TTF-1 and p40 coexpression and later bone recurrence

Patient Info: Anonymized, male, 70+ | Stage IV

Biomarkers: PD-L1 TPS 60%; ALK negative; ROS1 negative

Metastatic Site: lumbar vertebrae

The cancer recurred in the lumbar vertebrae about 4 months after surgery, and he died from cancer 9 months after the operation.

PubMed CentralRead more →

Stage I papillary lung adenocarcinoma treated with robotic segmentectomy despite an abnormal pulmonary vein

Patient Info: Anonymized, male, 70+ | Stage I

One year after surgery, there was no lung-cancer recurrence and no respiratory or right-sided heart-failure symptoms.

PubMed CentralRead more →

SMARCA4-deficient undifferentiated lung cancer with pleural disease and later spinal metastasis

Patient Info: Anonymized, male, 40s | Stage IV

Biomarkers: BRCA1 p.S1796 variant; TP53 p.; tumor mutational burden 12.6

Metastatic Site: spine

After chemotherapy and one cycle of nivolumab, a new 4.5 cm spinal metastasis caused cord compression and required surgery; further outpatient treatment was planned.

PubMed CentralRead more →

Stage II lung adenocarcinoma with severe atezolizumab-related myocarditis after surgery

Patient Info: Anonymized, female, 40s | Stage II

Biomarkers: PD-L1 TPS 50%

More than 1 year after atezolizumab was discontinued, there was no recurrence of the lung cancer.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Keegan's Survivor Story

Patient Info: Keegan Murphy, Male, 40s | Stage IV

Biomarkers: ALK fusion mutation

Metastatic Site: Lungs; lymph nodes; ribs/bone; abdomen

As of March 2024, Keegan had gone from Stage IV ALK-positive lung adenocarcinoma with tumors in the lungs, lymph nodes, ribs, and abdomen to no evidence of disease after alectinib and surgery.

MD AndersonRead more →

Stage IV Non-Small Cell Lung Cancer: Tim's Patient Story

Patient Info: Tim Monds, Male, 50s | Stage IV

Biomarkers: High PD-L1 expression

Metastatic Site: Other lung lobes / lung nodules

As of March 2024, Tim Monds was identified as a Stage IV lung cancer survivor involved in discussion of the PaCES early palliative-care project and broader lung cancer advocacy.

Lung cancer brain metastasis grew into a pre-existing meningioma

Patient Info: Anonymized, female, 70+ | Stage IV

Metastatic Site: brain

Six months after lung surgery, a pathologically confirmed brain metastasis developed beside and partly infiltrated a pre-existing meningioma. It was surgically removed, and the patient declined radiochemotherapy afterward.

PubMed CentralRead more →

Basaloid squamous lung cancer that regressed and later regrew

Patient Info: Anonymized, male, 70+

A lung nodule nearly disappeared without treatment, then regrew 2 years later and was resected as basaloid squamous cell carcinoma.

PubMed CentralRead more →

ALK-positive lung adenocarcinoma with a brain metastasis responding completely to brigatinib

Patient Info: Anonymized, male | Stage IV

Biomarkers: EML4-ALK fusion positive

Metastatic Site: pleura, brain

More than 10 years after the original lung-cancer surgery, switching from crizotinib to brigatinib produced a complete response in the brain metastasis, with ongoing treatment.

PubMed CentralRead more →

A primary lung adenocarcinoma that resembled metastatic thyroid cancer

Patient Info: Anonymized, female, 60s

Biomarkers: RET-GOLGA5 fusion

Alive 19 months after resection of the primary lung adenocarcinoma. The remaining miliary lung nodules were attributed to metastatic papillary thyroid cancer.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Ivy's Survivor Story

Patient Info: Ivy E., Female, 40s | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Bone: elbow, cervical spine/neck, rib, pelvis; brain

As of January 2024, Ivy reported no evidence of disease 1 year after right upper lobectomy, after years of response to EGFR-targeted therapy for initially Stage IV lung cancer.

The Patient StoryRead more →

Stage IV Lung Cancer: Deborah's Patient Story

Patient Info: Deborah Persinger, Female, 70+ | Stage IV

Metastatic Site: Brain

As of January 2024, Deborah was living actively 13 years after lung cancer diagnosis, with recurrent brain metastases managed through repeated Gamma Knife radiosurgery and ongoing MRI surveillance.

Cleveland ClinicRead more →

Stage III small-cell lung cancer had a complete response after chemo-immunotherapy and surgery

Patient Info: Anonymized, female, 50s | Stage III

Surgery showed a pathological complete response, and no recurrence or metastasis was found through 12 months of follow-up.

PubMed CentralRead more →

Stage I lung squamous cell carcinoma: surgery and IMRT for localized tracheal recurrence

Patient Info: Anonymized, Male, 60s | Stage I

Three months after IMRT, PET-CT and bronchoscopy showed no residual tracheal lesion, no mediastinal lymph-node involvement, and no metastasis; he remained alive in the third year of follow-up with 6-month monitoring.

PubMed CentralRead more →

Two synchronous Stage I squamous lung cancers treated with lobectomy

Patient Info: Anonymized, male, 70+ | Stage I

At 5 months after surgery, his overall condition remained good.

PubMed CentralRead more →

Lung cancer with limited spread, treated with a combination of therapies

Patient Info: Anonymized, Female

She remained free of recurrence for 164 months, with excellent quality of life and no neurological after-effects.

PubMed CentralRead more →